As gallant Shanghai fights its way out of the Omicron outbreak, multinational exhibitors at the China International Import Expo have expressed hope they will be able to participate in the fifth edition of the trade fair in November.
Pfizer, the global biopharmaceutical company, held a launch ceremony for Cibinqo – an oral, once-daily highly selective JAK1 (Janus kinase 1) inhibitor, for treating adult patients with moderate-to-severe atopic dermatitis in China on Sunday.
Biopharmaceutical company Pfizer announced on Friday that Lorbrena, the world's first third-generation anaplastic lymphoma kinase inhibitor, has been approved by China's National Medical Products Administration for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.
Biopharmaceutical company Pfizer announced on Friday that Lorbrena, the world's first third-generation anaplastic lymphoma kinase inhibitor, has been approved by China's National Medical Products Administration for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.